Barclays raised the firm’s price target on Novartis to CHF 85 from CHF 80 and keeps an Underweight rating on the shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVS:
- Pharming Novartis announces first commercial shipments of Joenja in U.S.
- TD Cowen pharmaceuticals analysts to hold analyst/industry conference call
- Novartis’ Sandoz announces EC approval for HCF Hyrimoz
- Novartis’ Entresto receives positive CHMP opinion for pediatric heart failure
- Novartis upgraded to Outperform from Neutral at Oddo BHF
